English
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Overview of attention for article published in Lung Cancer (01695002), December 2013
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (92nd percentile)
-
High Attention Score compared to outputs of the same age and source (89th percentile)
Readers on
- mendeley
- 107 Mendeley